ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Cancer
Conditions
Brief summary
A phase II single-arm trial of onapristone in combination with fulvestrant for women and men with ER-positive, PgR-positive or negative and HER2-negative locally advanced or metastatic breast cancer after progression on aromatase and CDK4/6 inhibitors. The study will enroll up to 39 participants.
Interventions
DRUGOnapristone
Onapristone is a type I antiprogestin which prevents the PgR from dimerizing and blocks ligand induced protein kinase-mediated phosphorylation of the PgR.
DRUGFulvestrant
Fulvestrant binds, blocks and degrades the ER, completely inhibiting ER signaling.
Sponsors
Context Therapeutics Inc.
University of Wisconsin, Madison
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Advanced ER+, (PgR positive or negative), and HER2 negative breast cancer. Advanced is defined as locally advanced or locoregionally recurrent or metastatic and not amenable to curative therapy. * Below-mentioned prior lines of therapy are allowed in the adjuvant and or metastatic ER+/HER2- setting. * Participants must have had prior endocrine therapy either in the adjuvant or metastatic setting (SERM (tamoxifen, raloxifene, toremifene) or any of the aromatase inhibitors (anastrozole, letrozole, exemestane), or oral selective estrogen receptor degrader (SERD) on a clinical trial either in the adjuvant or metastatic setting * Participants must have received prior therapy with oral cyclin-dependent kinase (CDK)4/6 inhibitors in the metastatic setting * Other standard therapies in the metastatic setting (such as mTOR inhibitors) are allowed * Patients who previously received any one of the standard adjuvant chemotherapy regimens in a curative setting are eligible for this study. * One line of prior chemotherapy in the metastatic setting is allowed (i.e. any single agent or doublet cytotoxic chemotherapy, not limited to xeloda). * Histologically and/or cytologically confirmed diagnosis of ER+, PgR+/- and HER2- breast cancer by local laboratory at diagnosis of metastatic disease. Hormone receptor positivity is defined as ER and PgR positivity in at least 1% cells by immunohistochemistry (IHC). HER2-negative breast cancer is defined as a negative in situ hybridization test or an IHC status of 0, 1+ or 2+. If IHC is 2+, a negative in situ hybridization test is required. * Measurable disease, i.e., at least one measurable lesion, as per RECIST 1.1 criteria. A palpable, and measurable breast mass is acceptable. * Eastern Cooperative Oncology Group (ECOG) Performance status ≤ 2 * Adequate organ function as defined by * aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≤ 2.5 times institutional upper limit. * Total bilirubin ≤ 1.5 × upper limit of normal (ULN), except for subjects with Gilbert's syndrome who may be included if their total bilirubin is ≤ 3.0 × ULN and direct bilirubin ≤ 1.5 × ULN. * Alkaline phosphatase (ALP) ≤ 2.5 times institutional upper limit with exception that ALP of \< 5 x ULN is acceptable in patients with elevated with ALP due to bone metastases (in the absence of liver metastases). * Serum creatinine \<1.5 × ULN. * Absolute neutrophil count (ANC) ≥1000/µL. * Participants with lymphopenia are eligible at the discretion of the treating provider * Hemoglobin (Hb) ≥ 8g/dL. * Platelet count ≥ 100,000/µL * Female participants must meet one of the following: * Postmenopausal for at least one year before enrollment, or * Surgically sterile (i.e., undergone bilateral oophorectomy), or * Premenopausal is defined as someone who has had menses at any time in the preceding 12 months. Premenopausal women who are eligible for this trial will require a Gonadotropin-releasing hormone (GnRH) analogue and treating physician may choose to monitor the ovarian function with laboratory tests to ensure a complete menopausal status with cessation of menses * Women of childbearing potential must have a negative pregnancy test within seven days of registration. Participants must have a negative pregnancy test seven to 10 days prior to starting study treatment * A formalin fixed paraffin embedded (FFPE) tumor biopsy block or up to 20 superplus frost slides with unstained histological sections at 4 micrometer thickness are required at the time of study entry. Archived tumor tissue acceptable (metastatic disease from non-bone and non-brain sites preferred, but primary breast or lymph node tissue is permitted) if obtained in the 18 months prior to study registration, otherwise a fresh biopsy will be required if deemed safe by the treating physician (minimal risk to patient). Confirmation of adequate and available tissue sample is to be determined by the site's pathologist. Tumor samples do not need to be shipped for eligibility purposes. Tumor samples do not need to be shipped until subject is confirmed eligible and is registered for treatment. * Ability to take oral medications (without crushing). Please refer to section 6.1.2 for directions on taking the study drug (onapristone). * To participate in the optional 18F-FFNP PET/CT imaging, the subject must have ER positive, HER2 negative, AND PgR positive disease and at least one extra hepatic lesion measuring at least 10 mm in size.
Exclusion criteria
* Prior treatment with an anti-progesterone agent. * Prior treatment with fulvestrant in the metastatic setting * Prior treatment with CDK4/6 inhibitors in the neoadjuvant/adjuvant setting * History of malignancy other than breast cancer within three years prior to registration except for adequately treated non-melanoma skin cancer, cervical carcinoma in situ. * History or presence of clinically active, and symptomatic central nervous system (CNS) metastasis: If the patient fulfills the following criteria, they will be eligible for the trial: * Completed prior therapy (including radiation and/or surgery) for CNS metastases ≥ 28 days prior to the start of study treatment and CNS tumor is clinically stable at the time of screening and patient is not receiving steroids and/or enzyme inducing anti-epileptic medications for brain metastases. * Participants with any of the following conditions: * Clinically significant illness or systemic disease as determined by the treating physicians. * Active hepatitis or uncontrolled infection or any other clinically significant cirrhosis or other disease that, in the opinion of the investigator would pose a risk to subject safety or interfere with the study evaluation, procedures or completion. Testing for infectious hepatitis is not required for the study. Treating provider may choose additional testing if indicated clinically. * Patients who have had systemic chemotherapy, or targeted therapy, within two weeks prior to starting study treatment or those who have not recovered from acute effects of any prior therapy to baseline or Grade ≤1. Grade 2 or higher exceptions include alopecia, up to grade 2 neuropathy or other grade 2 adverse events (AEs) or lab values not constituting a safety risk in the pinion of the treating physician. NCI CTCAE v5.0 will be used. * Co-administration with any prescriptions during the four weeks prior to first onapristone dosing and concerns for possible drug interactions should be discussed with the pharmacist * Patients who are pregnant or breast feeding * History of acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass grafting, coronary angioplasty, or stenting) or symptomatic pericarditis within 6 months prior to registration.. * Symptomatic congestive heart failure (New York Heart Association III-IV) * Clinically significant cardiac arrhythmias (e.g. ventricular tachycardia), complete left bundle branch block, high-grade atrioventricular block (AV) block (e.g. bifascicular block, Mobitz type II and third-degree AV block). * Any episode of atrial fibrillation in the prior 12 months. * QT interval \>480 msec. * Long QT syndrome or family history of idiopathic sudden death or congenital long QT syndrome. * Concomitant use of medication(s) with a known risk to prolong the QT interval and/or known to cause Torsades de Pointe that cannot be discontinued (within 5 half-lives or 7 days prior to starting study drug) or replaced by safe alternative medication. * Systolic blood pressure (SBP) \>160 mmHg or \<90 mmHg at screening.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Objective Response (ORR) | up to 17 months | Best overall response of complete response (CR) or partial response (PR), as per RECIST 1.1. Point and 95% interval estimate of ORR will be evaluated accounting for possibility of early futility stopping. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants Experiencing Progression Free Survival (PFS) | up to 17 months | Time from date of enrollment to the date of first documented disease progression or death due to any cause. PFS will be described with Kaplan-Meier (KM) Curve and its pointwise asymptotic 95% confidence bounds. Median PFS if reached will be extracted from this KM estimator. |
| Number of Participants With Disease Control (DCR) | up to 17 months | Best overall response of CR, PR or stable disease (SD) lasting for ≥ 24 weeks, as per RECIST 1.1. DCR will be estimated with relative frequency and exact two-sided 95% binomial confidence interval. |
| Time to Response | up to 17 months | Time from registration to first documented response (CR or PR) will be evaluated with a cumulative incidence where death will be as a competing risk to response. |
| Duration of Response | up to 17 months | Time between the first date of documented response to progression or death due to breast cancer. Duration of response will be assessed for a subgroup of subjects with observed response. The date of response will be denoted as time zero and time to progression or death will be evaluated with KM curve and 95% confidence interval (CI). Median time to response will be extracted from this KM curve. |
| Incidence of Treatment-Related Adverse Events | up to 17 months | Type, frequency and severity of adverse events and laboratory abnormalities (according to CTCAE version 5.0) will be summarized with descriptive frequency tables. See Adverse Events Section for detailed summary. |
Countries
United States
Participant flow
Recruitment details
Participants were recruited from the UW Hospital and Clinics and the Medical College of Wisconsin between October 2021 and January 2023.
Participants by arm
| Arm | Count |
|---|---|
| Onapristone In Combination With Fulvestrant All participants will receive onapristone 50 mg p.o. BID (twice) daily and fulvestrant (500 mg) intramuscular injection on days 1, 15 (cycle 1), then two weeks later (cycle 2, day1), then once every 28 days thereafter. A cycle is defined as 28 days.
There will be no breaks between dosing cycles.
Onapristone: Onapristone is a type I antiprogestin which prevents the PgR from dimerizing and blocks ligand induced protein kinase-mediated phosphorylation of the PgR.
Fulvestrant: Fulvestrant binds, blocks and degrades the ER, completely inhibiting ER signaling. | 11 |
| Total | 11 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Death | 1 |
Baseline characteristics
| Characteristic | Onapristone In Combination With Fulvestrant |
|---|---|
| Age, Customized 30 to 39 years old | 1 Participants |
| Age, Customized 40 to 49 years old | 1 Participants |
| Age, Customized 50 to 59 years old | 3 Participants |
| Age, Customized 60 to 69 years old | 5 Participants |
| Age, Customized 70 to 79 years old | 1 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 11 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 10 Participants |
| Region of Enrollment United States | 11 participants |
| Sex: Female, Male Female | 11 Participants |
| Sex: Female, Male Male | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 1 / 11 |
| other Total, other adverse events | 11 / 11 |
| serious Total, serious adverse events | 3 / 11 |
Outcome results
Primary
Number of Participants With Objective Response (ORR)
Best overall response of complete response (CR) or partial response (PR), as per RECIST 1.1. Point and 95% interval estimate of ORR will be evaluated accounting for possibility of early futility stopping.
Time frame: up to 17 months
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Onapristone In Combination With Fulvestrant | Number of Participants With Objective Response (ORR) | 0 Participants |
Secondary
Duration of Response
Time between the first date of documented response to progression or death due to breast cancer. Duration of response will be assessed for a subgroup of subjects with observed response. The date of response will be denoted as time zero and time to progression or death will be evaluated with KM curve and 95% confidence interval (CI). Median time to response will be extracted from this KM curve.
Time frame: up to 17 months
Population: Duration of Response could not be calculated because there was no response to treatment within the study time points.
Secondary
Incidence of Treatment-Related Adverse Events
Type, frequency and severity of adverse events and laboratory abnormalities (according to CTCAE version 5.0) will be summarized with descriptive frequency tables. See Adverse Events Section for detailed summary.
Time frame: up to 17 months
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Onapristone In Combination With Fulvestrant | Incidence of Treatment-Related Adverse Events | Participants Experiencing Grade 1 Adverse Events | 6 Participants |
| Onapristone In Combination With Fulvestrant | Incidence of Treatment-Related Adverse Events | Participants Experiencing Grade 2 Adverse Events | 1 Participants |
| Onapristone In Combination With Fulvestrant | Incidence of Treatment-Related Adverse Events | Participants Experiencing Grade 3 Adverse Events | 1 Participants |
Secondary
Number of Participants Experiencing Progression Free Survival (PFS)
Time from date of enrollment to the date of first documented disease progression or death due to any cause. PFS will be described with Kaplan-Meier (KM) Curve and its pointwise asymptotic 95% confidence bounds. Median PFS if reached will be extracted from this KM estimator.
Time frame: up to 17 months
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Onapristone In Combination With Fulvestrant | Number of Participants Experiencing Progression Free Survival (PFS) | 1 year PFS | 0 Participants |
| Onapristone In Combination With Fulvestrant | Number of Participants Experiencing Progression Free Survival (PFS) | 17 month PFS | 0 Participants |
Secondary
Number of Participants With Disease Control (DCR)
Best overall response of CR, PR or stable disease (SD) lasting for ≥ 24 weeks, as per RECIST 1.1. DCR will be estimated with relative frequency and exact two-sided 95% binomial confidence interval.
Time frame: up to 17 months
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Onapristone In Combination With Fulvestrant | Number of Participants With Disease Control (DCR) | 2 Participants |
Secondary
Time to Response
Time from registration to first documented response (CR or PR) will be evaluated with a cumulative incidence where death will be as a competing risk to response.
Time frame: up to 17 months
Population: Time to response could not be calculated as there was not a response to treatment within the study time points.